Horizon Therapeutics Public Limited Company

NasdaqGS:HZNP Stock Report

Market Cap: US$26.6b

Horizon Therapeutics Future Growth

Future criteria checks 3/6

Horizon Therapeutics is forecast to grow earnings and revenue by 16.4% and 8.3% per annum respectively while EPS is expected to grow by 15.4% per annum.

Key information

16.4%

Earnings growth rate

15.4%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate8.3%
Future return on equityn/a
Analyst coverage

Good

Last updated09 Oct 2023

Recent future growth updates

Recent updates

Horizon pays HemoShear milestone payment under pact to develop gout therapies

Sep 21

Horizon Therapeutics announces $500M buyback program

Sep 09

Horizon Therapeutics to expand footprint in Ireland

Aug 29

Horizon Therapeutics: This Core Biotech Company Is On Sale

Aug 19

Horizon Therapeutics: Buy The Dip For Slightly Risky, Catalyst Driven Growth

Jul 31

Horizon gets FDA approval for Krystexxa's use with methotrexate for uncontrolled gout

Jul 08

Earnings and Revenue Growth Forecasts

NasdaqGS:HZNP - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20254,7747282,2192,4965
12/31/20244,2345631,9062,1956
12/31/20233,7684781,654N/A6
6/30/20233,6444389061,041N/A
3/31/20233,5763721,0021,128N/A
12/31/20223,6295211,1321,258N/A
9/30/20223,7015741,2691,370N/A
6/30/20223,8137651,2691,415N/A
3/31/20223,7698621,1061,255N/A
12/31/20213,2265349071,035N/A
9/30/20212,957552734907N/A
6/30/20212,557518492604N/A
3/31/20212,187280515615N/A
12/31/20202,200390356556N/A
9/30/20201,819792197337N/A
6/30/20201,518517185316N/A
3/31/20201,376592173308N/A
12/31/20191,300573408426N/A
9/30/20191,29282328344N/A
6/30/20191,28297330341N/A
3/31/20191,26477306312N/A
12/31/20181,208-38178195N/A
9/30/20181,126-178216229N/A
6/30/20181,073-275198213N/A
3/31/20181,059-460183199N/A
12/31/20171,056-350280284N/A
9/30/20171,092-495275280N/A
6/30/20171,029-437335341N/A
3/31/2017997-212N/A340N/A
12/31/2016981-166N/A369N/A
9/30/2016915-12N/A365N/A
6/30/2016933-3N/A325N/A
3/31/201684914N/A319N/A
12/31/201575740N/A194N/A
9/30/2015616-16N/A69N/A
6/30/2015465-17N/A-18N/A
3/31/2015358-77N/A-42N/A
12/31/2014297-264N/A28N/A
9/30/2014223-335N/A6N/A
6/30/2014172-342N/A-5N/A
3/31/2014117-333N/A-32N/A
12/31/201374-149N/A-54N/A
9/30/201350-70N/A-60N/A
6/30/201332-82N/A-74N/A
3/31/201325-86N/A-79N/A
12/31/201219-88N/A-77N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HZNP's forecast earnings growth (16.4% per year) is above the savings rate (2.2%).

Earnings vs Market: HZNP's earnings (16.4% per year) are forecast to grow faster than the US market (14.9% per year).

High Growth Earnings: HZNP's earnings are forecast to grow, but not significantly.

Revenue vs Market: HZNP's revenue (8.3% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: HZNP's revenue (8.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if HZNP's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/10 13:59
End of Day Share Price 2023/10/05 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Horizon Therapeutics Public Limited Company is covered by 24 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Donald EllisAvondale Partners
Gary NachmanBMO Capital Markets Equity Research
Jason Matthew GerberryBofA Global Research